Phospho-EIF2S2 (Ser2) Antibody

Code CSB-PA790061
Size US$360
Order now
Image
  • Western blot analysis of extracts from C2C12 cells untreated or treated with PMA using eIF2b(phospho-Ser2) Antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) EIF2S2 Polyclonal antibody
Uniprot No.
Target Names
EIF2S2
Alternative Names
DKFZp686L18198 antibody; eIF 2 beta antibody; eIF-2-beta antibody; EIF2 antibody; EIF2B antibody; EIF2beta antibody; EIF2S2 antibody; Eukaryotic initiation factor 2 beta antibody; eukaryotic initiation factor 2-beta antibody; Eukaryotic translation initiation factor 2 beta antibody; Eukaryotic translation initiation factor 2 subunit 2 antibody; Eukaryotic translation initiation factor 2 subunit 2 beta 38kDa antibody; Eukaryotic translation initiation factor 2 subunit 2 beta antibody; Eukaryotic translation initiation factor 2 subunit beta antibody; eukaryotic translation initiation factor 2; subunit 2 beta; 38kDa antibody; IF2B_HUMAN antibody; MGC8508 antibody; PPP1R67 antibody; protein phosphatase 1; regulatory subunit 67 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Peptide sequence around phosphorylation site of serine 2 (M-S(p)-G-D-E) derived from Human eIF2?.
Immunogen Species
Homo sapiens (Human)
Clonality
Polyclonal
Purification Method
Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
eIF-2 functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S preinitiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B.
Gene References into Functions
  1. Data suggest that eukaryotic translation initiation factor 2 subunit beta (eIF2beta) is a therapeutic target for lung cancer. PMID: 29624814
  2. This study provides mechanistic insight into the role of eIF5-carboxyl terminal domain's dynamic interplay with eIF1 and eIF2beta PMID: 22813744
  3. These findings suggest that alpha and beta subunits of eIF2 interact with each other and the beta-subunit plays a critical role both in the regulation and function of eIF2. PMID: 18639529
Protein Families
EIF-2-beta/eIF-5 family
Database Links

HGNC: 3266

OMIM: 603908

KEGG: hsa:8894

STRING: 9606.ENSP00000364119

UniGene: Hs.429180

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*